Quick Takeaways
- MAVERICK CAPITAL LTD filed SCHEDULE 13G/A for Rocket Pharmaceuticals, Inc. Common Stock, $0.01 par value per share (RCKT).
- Disclosed ownership: 7.8%.
- Date of event: 30 Jun 2025.
MAVERICK CAPITAL LTD - 30 Jun 2025 SCHEDULE 13G/A Report for Rocket Pharmaceuticals, Inc. Common Stock, $0.01 par value per share (RCKT)
- Filing Manager
- MAVERICK CAPITAL LTD
- Reporting Manager
- Maverick Capital, Ltd.
- Symbol
- RCKT
- Shares outstanding
- 107,228,372 shares
- Disclosed Ownership
- 8,363,813 shares
- Ownership
- 7.8%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Aug 2025, 08:00:32 UTC
- Date of event
- 30 Jun 2025
- Previous filing
- 14 Apr 2025
- Next filing
- 13 Feb 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"MAVERICK CAPITAL LTD disclosed 7.8% ownership in Rocket Pharmaceuticals, Inc. Common Stock, $0.01 par value per share (RCKT) on 30 Jun 2025."
What Changed
- Previous schedule filing date: 14 Apr 2025.
- Current filing was accepted on 14 Aug 2025, 08:00.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Maverick Capital, Ltd. | 7.8% | 8,363,813 | 0 | 8,363,813 | /s/ Trevor Wiessmann* | By: Maverick Capital Management, LLC, its General Partner By: Lee S. Ainslie III, Manager | |
| Maverick Capital Management, LLC | 7.8% | 8,363,813 | 0 | 8,363,813 | /s/ Trevor Wiessmann* | Lee S. Ainslie III, Manager | |
| Lee S. Ainslie III | 7.8% | 8,363,813 | 0 | 8,363,813 | /s/ Trevor Wiessmann* | Lee S. Ainslie III, Manager |